# Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Source: https://onco.cc/trials/nct01059786/  
OnCo record `nct01059786` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pentostatin, Rituximab and Bendamustine in Hairy cell leukaemia, run by National Cancer Institute (NCI), active and no longer recruiting.

## Summary

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia is a phase 2 interventional study registered as NCT01059786 by National Cancer Institute (NCI), with 69 participants planned, started 2010-07-01 and due to reach its primary completion in 2022-12-15. Interventions recorded: Pentostatin, Rituximab, Bendamustine, Acetaminophen, Diphenhydramine, Epinephrine, Antihistamines, Corticosteroids, Bronchodilators, Intravenous (IV) Saline. Conditions recorded: Hairy Cell Leukemia.

Linked to the drug Pentostatin because the registry names it among its interventions and Hairy cell leukaemia among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01059786
- Phase: 2
- Setting: Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 69

## Sources

- ClinicalTrials.gov NCT01059786: https://clinicaltrials.gov/study/NCT01059786

## Connected records

- cancers: [Hairy cell leukaemia](https://onco.cc/cancers/hairy-cell-leukemia/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Pentostatin](https://onco.cc/drugs/pentostatin/), [Rituximab](https://onco.cc/drugs/rituximab/)

---
JSON: https://onco.cc/api/v1/entities/nct01059786.json